Treatment options for
metastatic urothelial carcinoma:
Challenge the expert
Publication date: 13 February 2023
Axel Merseburger, Enrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s viewpoint to create a lively debate.
Watch these two video discussions to expand your knowledge of first- and subsequent-line immunotherapy treatment options and see how the experts work together to find possible solutions.
After watching both videos, please remember to complete the evaluation survey as your feedback helps us to deliver the best learning experience.
Part 1: Therapy options in first-line and maintenance settings for patients with mUC
Part 2: Subsequent-line immunotherapy options for patients with mUC
About this activity
Learning objectives
After studying the content, participants will be able to:
- discuss current and emerging immune-based regimens for mUC and the clinical data supporting them
- debate how to best integrate and sequence new immunotherapy options in the landscape of mUC to achieve optimal clinical outcomes
- evaluate the importance of predictive factors to enhance patient selection and move to personalized care
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.
